ASO VISUAL ABSTRACT


## ASO Visual Abstract: Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node-Negative T1 Triple-Negative Breast Cancer

Kai Huang, MD<sup>1</sup>, James Jakub, MD<sup>2</sup>, Emmanuel Gabriel, MD<sup>2</sup>, Alvaro Moreno-Aspitia, MD<sup>3</sup>, and Sarah McLaughlin, MD<sup>2</sup>

<sup>1</sup>Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA; <sup>2</sup>Department of Surgery, Mayo Clinic Florida, Jacksonville, FL; <sup>3</sup>Jacoby Center for Breast Health, Division of Hematology Oncology, Mayo Clinic Florida, Jacksonville, FL

For patients with clinical T1 node-negative triple-negative breast cancer (TNBC), overall survival of upfront surgery followed by adjuvant chemotherapy was not inferior to those who underwent neoadjuvant chemotherapy (NACT).

Neoadjuvant chemotherapy was associated with a better outcome in cT1c patients who attained pCR (https://doi.org/10.1245/s10434-023-13977-4).



© Society of Surgical Oncology 2023 Published online: 14 August 2023

S. McLaughlin, MD

e-mail: McLaughlin.Sarah@mayo.edu

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.